
Quarterly report 2023-Q2
added 08-02-2023
NuVasive Net Debt 2011-2026 | NUVA
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt NuVasive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -238 M | -235 M | -82.8 M | 489 M | 485 M | 510 M | 472 M | 350 M | 439 M | 387 M | 283 M | 377 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 510 M | -238 M | 270 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
-26.7 M | $ 4.13 | -0.72 % | $ 155 M | ||
|
Apyx Medical Corporation
APYX
|
3.52 M | $ 3.67 | 3.09 % | $ 151 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 7.52 | -2.97 % | $ 1.13 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.22 | 3.26 % | $ 1.35 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 17.81 | 1.37 % | $ 418 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
-10.2 M | $ 5.64 | 7.84 % | $ 67.4 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 12.82 | 9.76 % | $ 363 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.61 | -0.08 % | $ 38 M | ||
|
LivaNova PLC
LIVN
|
-282 M | $ 71.86 | 1.32 % | $ 3.92 B | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 11.48 | 2.14 % | $ 411 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Orthofix Medical
OFIX
|
78.5 M | $ 11.65 | -3.48 % | $ 461 M | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.03 | - | $ 17.4 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
-2.42 M | $ 0.83 | -5.05 % | $ 34.7 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 26.93 | 0.26 % | $ 228 M | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.16 | -2.0 % | $ 881 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
Profound Medical Corp.
PROF
|
-55 M | $ 6.85 | -4.33 % | $ 207 M | ||
|
Insulet Corporation
PODD
|
218 M | $ 154.16 | -3.89 % | $ 10.8 B | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Sintx Technologies
SINT
|
-898 K | $ 2.35 | -2.08 % | $ 6.52 M | ||
|
Globus Medical
GMED
|
-511 M | $ 77.95 | -8.37 % | $ 10.5 B | ||
|
CONMED Corporation
CNMD
|
802 M | $ 36.76 | -3.52 % | $ 1.14 B | ||
|
Stryker Corporation
SYK
|
11 B | $ 285.47 | -2.98 % | $ 109 B | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 44.26 | -2.87 % | $ 1.3 B | ||
|
Integer Holdings Corporation
ITGR
|
1.18 B | $ 88.12 | 0.23 % | $ 3.06 B | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 79.96 | -3.44 % | $ 46.8 B | ||
|
Tandem Diabetes Care
TNDM
|
239 M | $ 15.48 | -16.19 % | $ 1.05 B |